Cellectis S.A.
IPOHome | Cellectis
- Headquarters
- Paris
- Employees
- 201–500
- Founded
- 1999
- Business Model
- B2B
- Website
- cellectis.com
- Total Funding
- $300.0M
- Last Round
- $140.0M Corporate RoundMay 2024
- Rounds
- 3
- Type
- Public
About
Clinical-stage biotechnology company using TALEN gene-editing platform to develop allogeneic CAR T-cell therapies for cancer.
Summary
Cellectis S.A. is a Biotech company based in Paris, France, founded in 1999. It has raised $300.0M in total across 3 rounds, most recently a $140.0M Corporate Round round in May 2024. Investors include AstraZeneca and Pfizer Ventures.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
May 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...